# Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

> **NCT02080468** · PHASE1 · COMPLETED · sponsor: **Aegerion Pharmaceuticals, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** lomitapide
- **DRUG:** EE/norgestimate

## Key facts

- **NCT ID:** NCT02080468
- **Lead sponsor:** Aegerion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-19
- **Primary completion:** 2014-04-24
- **Final completion:** 2014-04-24
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02080468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02080468, "Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02080468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*